1177 — Sino Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$98.09bn
- HK$101.92bn
- CNY31.83bn
Brief: Sino Biopharmaceutical Says TQB3205 Pan-Kras Inhibitor Receives NMPA Clinical Trial Approval
Brief: Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 Approved By NMPA
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Brief: Sino Biopharmaceutical Discloses Exclusive License Agreement For Rovadicitinib With Sanofi
Brief: Sino Biopharmaceutical Receives NMPA Approval For Rovadicitinib Tablet
Brief: Sino Biopharmaceutical Says NMPA Approved Benmelstobart Injection For Marketing
Sino Biopharmaceutical rises on progress of breast cancer drug
Sino Biopharm climbs most in five weeks on cancer drug development progress
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Sino Biopharmaceutical buys drugmaker Hangzhou Hygieia Biomedical for up to $172 million
Brief: Sino Biopharmaceutical Announces Acquisition Of 100% Equity Interest In Hygieia
Brief: Sino Biopharmaceutical Says Culmerciclib Capsule Approved By NMPA For Marketing
Brief: Sino Biopharmaceutical Says Tqf3250 Clinical Trial Approved By NMPA And FDA
Brief: Sino Biopharmaceutical Says Rotigotine Patch Approved For Marketing In China
Brief: Sino Biopharmaceutical Says LM-350 CDH17 Antibody-Drug Conjugate Receives Clinical Trial Approval From China's NMPA
Brief: Sino Biopharmaceutical Says TQB2102 Included In Breakthrough Therapeutic Designation Process In China
Brief: Sino Biopharmaceutical Says IND Application For TQF3250 Accepted By NMPA